Recombinant Human FLT4 protein(Met1-Ile776), hFc-tagged

• Cat.No.: FLT4-889H
• Product Overview: Recombinant Human VEGFR3 (NP_002011.2)(Met 1-Ile 776) was expressed in HEK293 with the fused Fc region of Human IgG1 at the C-terminus.

Specification

• Source: HEK293
• Species: Human
• Tag: Fc
• Protein length: Met1-Ile776
• Form: Lyophilized from sterile PBS, pH 7.4. Normally 5 % - 8 % trehalose, mannitol and 0.01% Tween80 are added as protectants before lyophilization.
• Bio-activity: Measured by its binding ability in a functional ELISA. 1. Immobilized recombinant human VEGFR3 at 5 μg/ml (100 μl/well) can bind recombinant human VEGF-D at a linear range of 62.5-2000 ng/ml. 2. Immobilized recombinant human VEGF-C at 10 μg/ml (100 μl/well) can bind recombinant human VEGFR3 at a linear range of 0.64-80 ng/ml. 3. Scatchard analysis showed the affinity constant (Kd) of recombinant human VEGF-C bound to recombinant human VEGFR3 was 1.4 nM.
• Molecular Mass: The recombinant human VEGFR3/Fc is a disulfide-linked homodimeric protein. The reduced monomer consists of 990 amino acids and predicts a molecular mass of 111.3 kDa. As a result of glycosylation and proteolytic cleavage, rhVEGFR3/Fc migrates as three bands (160, 85, 75 kDa) corresponding to the full length and the cleaved two polypeptides respectively in SDS-PAGE under reducing conditions.
• Endotoxin: < 1.0 EU per μg of the protein as determined by the LAL method
• Purity: > 97 % as determined by SDS-PAGE
• Storage: Samples are stable for up to twelve months from date of receipt at -20°C to -80°C. Store it under sterile conditions at -20°C to -80°C. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
• Reconstitution: It is recommended that sterile water be added to the vial to prepare a stock solution of 0.2 ug/ul. Centrifuge the vial at 4°C before opening to recover the entire contents.

Gene Information

• Gene Name: FLT4 fms-related tyrosine kinase 4 [ Homo sapiens ]
• Official Symbol: FLT4
• Synonyms: FLT4; fms-related tyrosine kinase 4; vascular endothelial growth factor receptor 3; PCL; VEGFR3; FLT-4; VEGFR-3; soluble VEGFR3 variant 1; soluble VEGFR3 variant 2; soluble VEGFR3 variant 3; fms-like tyrosine kinase 4; tyrosine-protein kinase receptor FLT4; FLT41; LMPH1A
• Gene ID: 2324
• mRNA Refseq: NM_002020
• Protein Refseq: NP_002011
• MIM: 136352
• UniProt ID: P35916

Reviews

09/05/2022

The catalytic activity of FLT4 is very strong, which can significantly improve the selectivity and yield of chemical reactions, and its application potential is great.

09/26/2019

We were reassured that the quality of FLT4 was consistent.

03/23/2019

Using FLT4 for experiments, I can focus more on experimental design and data analysis without worrying about the reproducibility of experimental results.

Q&As

Does FLT4 protein correlate with tumor-related markers?

FLT4 protein is associated with various tumor-related markers such as malignant lymphoma, breast cancer, and lung cancer.

Is there a relationship between FLT4 protein and lymphedema?

FLT4 protein is a key regulator of lymphedema and plays an important role in lymphangiogenesis and lymphatic drainage.

Is FLT4 protein associated with congenital lymphedema?

Yes, mutations in the FLT4 protein can lead to congenital lymphedema, a condition caused by abnormal lymphatic vessel development.

What is the potential of FLT4 protein in cancer treatment?

The protein is considered an important target in anticancer therapy, and inhibition of its activity may reduce tumor angiogenesis and metastasis.

What is the role of FLT4 protein in pulmonary hypertension?

FLT4 protein plays an important role in pulmonary hypertension, and upregulation of its activity may lead to pathological changes such as vascular remodeling and pulmonary artery stenosis.

What is the role of FLT4 protein in angiogenesis?

This is involved in the regulation of angiogenesis and lymphangiogenesis by binding to vascular endothelial growth factor C (VEGF-C) and vascular endothelial growth factor D (VEGF-D).